A New Weapon Against Chemotherapy-Related Nausea and Vomiting in Cancer Treatment: Varubi (rolapitant)

When I inform patients before chemotherapy, one of their main concerns is how much nausea they will experience. A new drug, Varubi (rolapitant), was approved on 2 September by the United States Food and Drug Administration (FDA) because it successfully prevented delayed chemotherapy-related nausea and vomiting in adults.
As everyone now knows, chemotherapy is effective in many cancers and produces positive results. Drugs used to prevent cancer cell growth and multiplication and destroy these cells circulate throughout the body, creating widespread effects.
However, chemotherapy can cause side effects. Patients may experience problems affecting daily life, particularly nausea and vomiting, as well as fatigue, loss of appetite and constipation. Medicines developed through extensive research now make protection against these effects possible. The FDA recently announced one notable study in this area.
Varubi (rolapitant), combined with the anti-nausea drugs granisetron and dexamethasone, prevented delayed chemotherapy-related nausea and vomiting. It is a neurokinin-1 (NK-1) receptor antagonist. NK-1 receptors play a critical role in nausea and vomiting triggered by some chemotherapies, particularly in the delayed period (24 – 120 hours afterward). The most frequently reported side effects of Varubi were low white blood cell counts (neutropenia), hiccups, reduced attention and dizziness.
Dear friends, it appears we now have another weapon against chemotherapy-related nausea and vomiting, which can adversely affect cancer patients' lives. We will closely follow whether this drug receives approval in our country and share developments.
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.